Member Info for sadoldgit

Interesting after reading through a couple of times.

'SRA737 has completed two phase 1/2 studies in patients with advanced cancers, one as a single agent and the other in combination with low-dose gemcitabine. An Investigational New Drug ("IND") application has now been approved by the US Food & Drug Administration.'

Rather poor if due to awaiting manufacture of compound.

Look forward to investor meet.

No mention of commencement of toxicology start. Preparing for toxicology studies.

Healthy cash balance.

Mr Parker where is this early in the New Year toxicology start going to take place?

I am sure questions have been sent that l sincerely hope they will address.

What l do find odd is an investor meet but lack of RNS. For what purpose is this route taken?

Whoops forgot to add it has already been stated that it may be of benefit to use 1802 as a back up treatment for 1801.

in this instance in combo therapy with 1801 and 1802 cannot be ruled out.

Ulcerative colitus and Crohns Disease?

Regards

Good evening DP64

A ggod pst by HbD regarding buying of a company mainly due to extreme interest in a particular pipeline product.

Notice how the offer is raised when approval for a stage is given as a certain element of doubt is removed.

All pharmas will attempt this low balling as after all it is a business and there to make as much money as possible.

In the end they paid over 900 million upfront as opposed to initia offer around 350 million.

Timescales.

It takes months for negotiations.

My belief is that we are in a not too dissimilar situation.

Hence why toxicology results are so important.

In effect if results are good and all that means is we do not suffer from the boxed warnings placed on all other inhibitors of Jak1 2 and 3. This applies to immuno thereapy in auto immune diseases eg Lupus, Psoriasis, Alopecia, Psoratic Arthritus.

We also have immuno oncology and the sdverse effects of Jak1 2 and 3 are nowhere near as imortant or indeed boxed warning or to be more precise black box warning limited.

For example if treating a cancer with a prognosis of 18 months life expectancy it is not going to matter for long term toxicology effects 7 years down the line if the life expectancy is now expected to be 3 to 5 years.

Efficacy in this instant is paramount to a plus.

The downside of course is unwanted off target advers events.

In evaluating suitability for use the plusses are taking with the negatives tosee a net gain.

This of course determines demand for the product which is all important to commercialisation value and of course the amount that an interested company will be prepared to pay for the product,

What they are prepared to pay and what they initially offer should not be confused.

Now interestingly we have 1802 which has and is still gaining very strong long term patent protection.

Now one more thing of extreme importance is that our TYk2 Jak 1 inhibitor 1802 has a higher jak 1 2 and 3 content.

Interestingly this is still way below what other pharmas have in their auto immune TYK2 combined Jak 1 2 and 3 inhibitors albeit with differing individual JAK weighting.

I have gone on a tad as usual.

if you have read this and is of benefit to you then good.

But i will stress that the market is getting ever competitive and the small bio sector is suffering hugely from lack of investment and decent finance.

We are not alone

My reckoning is difficulties experienced in obtaining in combo therapy.

Chemo not a problem.

But look at the big companies who have PD-1 and Parp inhibitors. How would you gain partnership and how much of tge takings does tge big guy want?

SO had a Wee1 inhibitor that SO were looking at using in combo with 737.

Both 737 and the Wee1 inhibitor were returned after GSK takeover.

DDR at P53 checkpoint is present in most cancers with High Grade Serious ovarian cancer at late st stage over 90%.

In combo therapy can work but a lot involved including genetics. Age of patient, sex of patient to name a couple.

Acrivon with the acquired Prexsasertib now named ACR-368 has been granted fast track in endometrial cdncers and Acrivon busy exploring other cancers.

Prexasertib was discontinued due to off target effects..

Acrivon uses precision technology to administer the drug with regards to dosing. Careful patient selection which fit genetically

Difference in success whether the cancer cell is wild type or non wild type.

In combo therapy can allow lower doses with benefit of reduced toxicity.

At the same time caution needs to be exercised on combo therapy as their exist compatability issues between differing oncology treatments.

737 plus low dose gemcitabine with a PD-1 inhibitor resulted on startling efficacy in preclinical. Use of mice here and thus was for small cell lung cancer.

Big pharma does not like competitors.

Their aim is to make money.

There is also a huge cost involved in running trials which can run easily into the hundreds of millions especially when entering phase 3 clinical trials and this is to prove it is better than the current standard treatment.

Regards.

I

Https://veri.larvol.com/news/sra737/drug

In my opinion one of the two species would be primates

Reasoning is that we are looking at pharmacodynamics ie tge effect of compound on the body as opposed to what may be regarded as toxicity ie pharmokinetic effect ie what the body does to the compound.

Whilst toxicities can be detected in secretions and the liver long term adverse events that can arise need monitoring of effects on heart and vital organs.

Primates will be more expensive and preparation of the primates will need settling on period.

They don't need to be stresses and will require acclimatisation to new surroundings.

Much more involved than a few hamsters running peddling a wheel in a cage.

I may be wrong.

Good to see the sareum pipeline updated.

That is a very interesting chain of thinking Num4.

Many inhibitors now are no longer competitive due to the issues of toxicity with jak 1 2 and 3.

We are heavily selective of Tyk2 over these jakis that it is almost non existent.

Baricitinib

Tofacitinib

Ruxolitinib

Beprocitinib

Ropsacitinib

There are many more and we look at the moment to be around the best as indicated in SAD and MAD studies.

I believe confirmation required via long term toxicology studies will put the icing on the cake.

The pathways interleukin interferon targets should indicate satisfactory efficacy in many Indications with psoriasis being one albeit a very competitive field as Tim expressed himself a while back.

We could always enquire as to what indications Sareum.are looking to enter.

Or will this decision be left to the long waiting interested party that as John Reader said 'well give us some data?'

In effect then Aber

What are Sareums intention to progress 737.

Has there been any interest from those that were going to form an orderly queue?

It is a big question as surely you would vet as far as can be done those that show interest.

No good licensing to a company that choses to remain anonymous.

737 has good results in some cancers albeit at preclinical stage.

Importantly is what actual progress or development the anonymous US private was made?

Sareum have not long had 737 ownership.

The further funding for a million reduced market cap by around 4 million.

There are many options ut would be good to know what Sareums intentions are with all compounds.

Is a takeover to be ruled out?

One thing we don't want is a delay in toxicology studies, I fully understand that there is a lot of planning of trial design. Do we have formulated compound sufficient for studies?

Much will unfold on Tuesday.

Regards

Ideally cash runway

Commencement of toxicology studies

Continuing translational studies

Intentions with 737. Ie are they looking to partner or on licence?

Are they looking for further fundraising and if so when?

Who is not calm you little fool.?

I pointed out share price manipulation which you found absolutely astounding the amount that was written here.

Why do you need to keep entering the word fact on something so insignificant all the time. Is it to give some sort of credibility? It dont work very well with me sonny.

You remember as a 13 year old? I dont think that was many moons ago.

So at the age of 13 did you go out and purchase some shares? How did you repay this adult?

So you are now agreeing with me that there is manipulation in place from your statement below, 'everyone knows AIM and market is dishonest'

Now the 7% valuation you are using is that of 7% of market Cap based at 12.5 p per share.

In actual fact the 12.5p per share has resulted in a net reduction of over 5 million approxof market cap prior to raise.

You have failed to comprehend the jist of the topic.

Many buys and little to no rise. then we have a largish trade of around 800,000 at less than the raise price of a share.

As I said similar to crypto where there exist whales that can control the SP. They can affect the SP

All I am saying is I believe this is happening here.

In addition to that there will also be multiple posters that will push negativity such as your friend wolfie.

One more thing sonny.

'The reason for the tip was that he owned the printing company that was printing the annual report so he knew what wa shappening'

You sound like a very gullible 13 year old.

So now we can establish an important fact in that you know as the market is dishonest their exist dishonest practices and dishonest people Many claim to be invested yet lie.

Are you related to that wolfie chappie over on ADVFN he comes out with as much excreta as you do.

what is your golf handicap about 25 i reckon.

Good evening webstar.

NSCLC and not SCLC which in the field of oncolgy is a big difference.

Large tumours.

Most likely a PD-1 inhibitor and probably chemo as a combo.

Programmed Death is what the PD stands for. Cancer cells are not apoptic and hence do not have programmed cell death.

CHK1 inhibition has been carried out with PARPi and PD-1 in preclinical studies and indeed with incombo with chemo therapy.

Regards and thanks for the input

Yes FG but correct me if I am wrong but the Share price was at a 25% discount.

Plenty of buys come in, yet funnily enough soon as the SP rises along comes a largish sell or couple of sells which wee on the proverbial matches.

Now there exists whales in crypto currencies. Do you understand this and how they can affect the price along with their associated rampers and derampers.

Are you that naive to believe that this cannot happen or has not happened in AIM?

Funnyguy are you saying that there is no manipulation of the SP price?

Do you believe that there is no manipulation of SP on AIM?

Do you believe that there is no manipulation of SP with Sareum.

What was Riverfort Globals objectives apart from reducing the SP by 90% and icreasing the shares by 50%?

Are you one of Wolfies comrades over on ADVN? He claims to have comrades over on this LSE chatboard?

Have a good evening whare ever you reside, nowhere near a golf course i would think.

Stephen parker has orhestrated the return of 737, so credit is due there.

As for the orderly queue which indicates more than one party, he can be selective as to who and what is the best option.

737 likely to be to low upfront with highish back end milestones on commercialisation.

i would guess around 3 to 6 months for this to materialise.

As you state Gunner68 a few million upfront will keep us away from begging.

HNWI's tend not to lose out and that includes institutions.

News to follow soon and strongly believe within the next 8 trading days RNS half yearly result update.

Regards

Take a look at share price manipulation.

There is an Ai answer which fits the bill nicely.

I think Laz posted a little while ago on this one.

Regards

Surfie you have been reading too many of Riceyboys posts. A great neutral poster like yourself.

If I am wrong l suggest you then look at his posting history so you can obtain a balanced view like riceyboy has.

Regards